socalTECH

JUNE 11, 2021

The company begins trading this morning on the Nasdaq Global market under the ticker symbol JANX. According to the company, the gross proceeds from the effort are expected to be $193.8M. Janux Therapeutics is developing T cell engager immunotherapies.

Pricing 113

Pricing Avalon Capital Marketing 113

socalTECH

MARCH 31, 2020

San Diego-based AristaMD , a developer of telehealth software, which allows primary care providers to conduct and document electronic medical consultations, has raised $18M in a Series B funding round. The company said the funding will go to towards accelerating expansion of its platform across the country. READ MORE>>.

Funding 140

Funding Avalon San Diego Platform 140

socalTECH

MARCH 29, 2021

San Diego-based Fortis Therapeutics, a biotechnology startup developing treatments for late-stage prostate cancer and multiple myeloma, has raised $40M in a Series A financing, the company said on Monday.

Avalon 113

Avalon San Diego Research Funding 113

socalTECH

JULY 28, 2020

San Diego-based telemedicine and telehealth software developer AristaMD has added another $6M to the company's Series B, bringing the total to $24M, the company said on Monday. AristaMD develops telehealth software used for virtual consultations, allowing primary care physicians to consult with medical specialists virtually.

Funding 100

Funding Avalon San Diego Software Development 100

Xconomy

SEPTEMBER 27, 2016

[ Note: The headline has been corrected to better describe the company’s type of funding. Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. 9/27/16, 2:09 p.m. Bregua Corp., We’re not inventing anything on the ADC,” he said.

Avalon 40

Avalon Funding Startup San Diego 40

socalTECH

NOVEMBER 13, 2019

San Diego-based COI Pharmaceuticals , the life sciences incubator and support entity created by Avalon Ventures to support its portfolio companies, says that one of its companies, Calporta Therapeutics , has been acquired by Merck. The deal is worth up to $576M, including upfront payments and contingent milestone payments.

Avalon 124

Avalon San Diego Incubator Technology 124

socalTECH

NOVEMBER 22, 2013

San Diego-based Avalon Ventures announced this morning that it has launched a new company, Sitari Pharmaceuticals , with $10M in a Series A financing. READ MORE>>. disease celiac lifescience biotech capital venture glaxosmithkline pharmaceuticals sitary ventures avalong'

Avalon 153

Avalon San Diego Capital Funding 153

socalTECH

APRIL 17, 2017

Monrovia-based biopharmaceuticals developer Xencor announced this morning that it has named Kevin Gorman, ph.D., Gorman is the CEO of Neurocrine Biosciences, where he has been since 1993; he previously was an investor at Avalon Medical Partners, L.P. who the company said will not stand for re-election to its board.

Avalon 113

Avalon Monrovia Develop Development 113

socalTECH

JULY 14, 2017

San Diego-based StackIQ , a developer of "bare metal" provisioning software, has been acquired by Teradata , Teradata said on Thursday. StackIQ was venture backed by Anthem Venture Partners, Grayhawk Capital, Avalon Ventures, and crowdfunding site OurCrowd. Financial terms of the acquisition were not announced. READ MORE>>.

Avalon 113

Avalon Anthem San Diego Acquisition 113

socalTECH

OCTOBER 22, 2014

San Diego-based StackIQ , which develops IT automation tools for the enterprise, has raised $6M in a Series B funding round, according to the company. The new funding came from Grayhawk Capital, Keshif Ventures, DLA Piper, and OurCrowd, as well as Anthem Venture Partners and Avalon Ventures. The company is led by Tim McIntire.

Avalon 174

Avalon Anthem San Diego Venture Capital 174

socalTECH

SEPTEMBER 27, 2016

San Diego-based Fortis Therapeutics , a new biotech company in the immuno-oncology area, announced this morning that it has raised $18M in a Series A funding. The funding was led by Avalon Ventures and also included Bregua Corporation, Lilly Asia Ventures, Osage University Partners, and Vivo Capital. READ MORE>>.

Avalon 100

Avalon San Diego Research Capital 100

socalTECH

JANUARY 9, 2014

San Diego-based Avelas Biosciences announced today that it has raised $6.85M in a Series B funding round, for the company''s technology for illuminating cancer cells. The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor. READ MORE>>.

Avalon 138

Avalon San Diego Funding Capital 138

socalTECH

MARCH 5, 2013

San Diego-based Carolus Therapeutics , a developer of biopharmaceuticals aimed at treating acute and chronic inflammation, has scored $2.25M in a debt funding round, according to financing provider Square 1 Bank. Terms of the debt funding were not announced by the companies. READ MORE>>.

Avalon 147

Avalon Funding San Diego Develop 147

socalTECH

AUGUST 18, 2016

San Diego-based biopharmaceuticals developer Avelas Biosciences has raised $20M in a Series C funding, according to the company. and laos included Ervington Investments Limited and Alexandria Venture Investments plus Avalon Ventures, Bregua Corporation, and WuXi Healthcare Ventures. Andrei Petrov, Ph.D., READ MORE>>.

Avalon 100

Avalon San Diego Invest Funding 100

socalTECH

NOVEMBER 28, 2016

San Diego-based biotechnology developer Synthorx announced today that it has named Patrick J. Synthorx is focused on developing novel protein therapeutics, and is venture backed by RA Capital Management, Avalon Ventures and Correlation Ventures. The company announced a funding round in July. READ MORE>>.

Avalon 100

Avalon San Diego Capital Funding 100

socalTECH

JULY 20, 2016

San Diego-based Synthorx , a developer of protein therapeutics technology, said it has raised $10M in a Series B financing this morning. The funding was led by RA Capital Management, and also included Avalon Ventures and Correlation Ventures. RA Capital Management's Andrew Levin joins the company's board with the funding.

Avalon 100

Avalon San Diego Research Capital 100

socalTECH

SEPTEMBER 10, 2014

San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. in a Series B funding.

Avalon 147

Avalon San Diego Venture Capital Research 147

socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The company now trades as ANAB on the NASDAQ Global Select Market.

Avalon 100

Avalon San Diego Pricing Invest 100

socalTECH

AUGUST 13, 2014

The company was trading around $17.52 The company raised $100M in the IPO. The company priced at the high end of its initial estimated IPO range, which was $14.00 The company is developing treatments for disorders of the inner ear. million shares of its common stock at $16.00 per share last night.

Avalon 138

Avalon San Diego Pricing Acquisition 138

socalTECH

APRIL 30, 2014

San Diego-based biopharmaceuticals developer Otonomy --which is developing treatments for inner and middle ear disorders--has roped in a big, $49M funding, the company announced this morning. The company said the new funding will go towards its product pipeline and a potential filing for regulatory approval of its lead compound.

Funding 138

Funding Avalon San Diego Capital 138

socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. and $16.00

Pricing 100

Pricing Avalon Southern California Venice 100

socalTECH

AUGUST 4, 2014

San Diego-based Otonomy , which is developing treatments for diseases of the inner and middle ear, set its estimated IPO pricing range Friday. The company indicated in a filing that it now expects its IPO at between $14.00 and $16.00 Otonomy has applied to list on the NASDAQ Global Market as OTIC. READ MORE>>.

Pricing 147

Pricing Avalon San Diego Acquisition 147

socalTECH

JUNE 23, 2015

La Jolla-based Ankasa Regenerative Therapeutics , a company developing stem-cell based products aimed at organ and tissue regrowth, repair, and healing, has raised $8.5M in a Series A funding, the company said this morning. The funding was led by Avalon Ventures, and also included Hereaus Medical and Correlation Ventures.

Avalon 100

Avalon Organization Funding Startup 100

socalTECH

DECEMBER 2, 2013

The developer of portable oxygen concentrators -- used as an alternative to bulky, oxygen canisters for those with chronic respiratory conditions like COPD -- said it plans to raised up to $86.25M in its public debut. The company''s IPO is being underwritten by J.P. Morgan, Leerink Swann, William Blair, and Stifel. READ MORE>>.

Avalon 153

Avalon Acquisition Marketing Develop 153

socalTECH

JULY 22, 2016

San Diego-based AristaMD , which is developing software tools to help coordinate referrals by physicians to specialists, has raised $11M in a Series A funding round. The funding was led by Avalon Ventures, and also included Correlation Ventures.

Avalon 100

Avalon San Diego Tool Research 100

socalTECH

MARCH 21, 2014

San Diego-based Otonomy , a biopharmaceuticals company developing treatments for disorders of the inner and middle ear, said Thursday that it has added Vickie Capps to its board of directors. Capps was previously EVP, CFO, and treasure for DJO Global, and also previously had served at Ernst & Young. READ MORE>>.

Avalon 138

Avalon San Diego Capital Develop 138

socalTECH

DECEMBER 4, 2015

The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types.

UCLA 100

UCLA Avalon San Diego Los Angeles 100

socalTECH

SEPTEMBER 4, 2013

According to the company, the funding was led by OrbiMed Advisors, and also included Aperture Venture Partners, Osage University Partners, as well as Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech. Khuong of OrbiMed wil join the company''s board with the funding. READ MORE>>.

Avalon 138

Avalon San Diego Equity Funding 138

socalTECH

JULY 17, 2014

for San Diego''s Veredezyne , which is developing biofuels and biochemicals processes. billion invested in companies across the nation, which PwC and the NVCA said was the highest level since Q4 of 2000. Patrick Soon-Shiong, which raised $135M in a funding; El Segundo-based Prodege (aka Swagbucks), which raised $60.1M

Southern California 240

Southern California El Segundo Culver City Orange County 240

socalTECH

JUNE 9, 2009

San Diego-based aFraxis , a stealth-mode firm developing treatments for Fragile X Syndome and autism, has raised $750,000 in a funding round, according to a regulatory filing by the firm Tuesday. Details on the funding have not been announced, however, the company is venture backed by Avalon Ventures.

Avalon 100

Avalon San Diego Venture Capital Capital 100

socalTECH

JUNE 9, 2010

San Diego-based Otonomy , a biopharmaceuticals firm developing drug therapies to treat inner and middle ear disorders, has raised $10.56M as part of an ongoing, $26.0M Source of the new funding was not disclosed, however, one of its founders, Jay Lichter, is at San Diego venture firm Avalon Ventures, which has previously backed the company.

Avalon 159

Avalon San Diego Venture Capital Capital 159

socalTECH

JUNE 4, 2012

San Diego-based Awarepoint , which develops real-time, location systems used for tracking patents and assets in a healthcare environment, said today that it has raised $14M in an additional financing round. of the new investment round, which the company said will go to expand its services, client management, and manufacturing capabilities.

Avalon 140

Avalon San Diego Patents Invest 140

socalTECH

JULY 12, 2010

The firm said the contract covers developing antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats. The company said the contact covers a two year period. San Diego-based AnaptysBio announced this morning that it has received $1.5M

Outsource Development 140

Outsource Development Avalon San Diego Research 140

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday.

Avalon 40

Avalon San Diego Study Invest 40

socalTECH

JUNE 1, 2010

Chumby develops a Wi-Fi enabled, Internet device which acts both as a clock as well as a connection into internet services like Weather, news, and more. According to the filing, the firm is in the midst of raising up to $9.786M in the round.

Avalon 150

Avalon San Diego Venture Capital News 150

socalTECH

OCTOBER 4, 2010

Chumby has previously raised funding from Avalon Ventures, JK&B Capital, Masthead Venture Partners, and O'Reilly AlphaTech Ventures. Chumby's Internet device allows users to run information widgets, and includes tools for developers which makes it easy to create those software widgets to connect to Internet services. READ MORE>>.

Avalon 145

Avalon San Diego Venture Capital Software 145

socalTECH

JULY 18, 2013

invested across 45 companies. The biggest deal for the quarter was for Venice-based photo messaging app developer Snapchat , which raised a huge, $60M funding round in the quarter. Across the region, Los Angeles led in terms of dollars and deals, with $277.4M Orange County was second, with $161.9M

Southern California 187

Southern California Venture Capital Tech Coast Angels Capital 187